We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

103 hedge funds and large institutions have $677M invested in BioCryst Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

152% more call options, than puts

Call options by funds: $11.8M | Put options by funds: $4.71M

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

47% more capital invested

Capital invested by funds: $461M → $677M (+$216M)

17% more funds holding

Funds holding: 88 → 103 (+15)

Holders
103
Holders Change
+15
Holders Change %
+17.05%
% of All Funds
2.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
33
Increased
38
Reduced
15
Closed
17
Calls
$11.8M
Puts
$4.71M
Net Calls
+$7.14M
Net Calls Change
+$3.88M

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$48.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17M
3
BFA
BlackRock Fund Advisors
California
+$16.2M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.9M
5
BIT
BlackRock Institutional Trust
California
+$8.42M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.7M
2
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$12.3M
3
RCM
RA Capital Management
Massachusetts
-$11.2M
4
DM
Deerfield Management
New York
-$9.61M
5
Millennium Management
Millennium Management
New York
-$4.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$139M +$48.9M +5,023,841 +86%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$137M +$17M +1,743,844 +19%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$68.2M +$12.9M +1,329,584 +33%
RCM
4
RA Capital Management
Massachusetts
$40.8M -$11.2M -1,148,927 -26%
BFA
5
BlackRock Fund Advisors
California
$32.6M +$16.2M +1,659,980 +185%
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$30.9M +$3.44M +353,158 +17%
State Street
7
State Street
Massachusetts
$28.7M +$5.93M +609,035 +37%
Vanguard Group
8
Vanguard Group
Pennsylvania
$26.1M +$2.57M +264,629 +15%
BIT
9
BlackRock Institutional Trust
California
$24.8M +$8.42M +865,445 +80%
VM
10
VHCP Management
New York
$22.2M – – –
CAM
11
Cormorant Asset Management
Massachusetts
$14.9M – – –
QF
12
QVT Financial
New York
$9.25M +$1.95M +200,000 +38%
BIM
13
Bogle Investment Management
Massachusetts
$7.98M +$6.09M +626,013 New
Morgan Stanley
14
Morgan Stanley
New York
$6.26M -$333K -34,272 -7%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.71M +$879K +90,376 +32%
BA
16
BlackRock Advisors
Delaware
$4.69M +$3.48M +357,957 +3,604%
TCIM
17
TIAA CREF Investment Management
New York
$4.48M +$3.42M +351,228 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$4.14M +$2.27M +233,580 +256%
Jennison Associates
19
Jennison Associates
New York
$4.09M -$366K -37,615 -10%
OAM
20
Oxford Asset Management
United Kingdom
$3.73M +$2.86M +293,605 New
Two Sigma Investments
21
Two Sigma Investments
New York
$3.29M +$2.51M +257,889 New
Charles Schwab
22
Charles Schwab
California
$3.19M +$2.2M +226,060 +946%
Northern Trust
23
Northern Trust
Illinois
$3.04M +$1.2M +123,186 +107%
BIM
24
BlackRock Investment Management
Delaware
$2.86M +$2.18M +224,551 New
Marshall Wace
25
Marshall Wace
United Kingdom
$2.79M +$2.12M +218,413 New
1
2 3 4 5

BCRX Hedge Fund Activity: Q2 2014 in Review

103 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2014, worth a combined $677M — up 47% from $461M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BCRX positions and 17 closed out — a net gain of 16 holders — while 38 added to existing stakes and 15 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $48.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.7M sold.

  • 103 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2014, up from 88 in Q1 2014.
  • Funds reported $677M of BioCryst Pharmaceuticals stock for Q2 2014, up 47% quarter-over-quarter.
  • 33 funds opened new BioCryst Pharmaceuticals positions in Q2 2014 and 17 closed out, a net change of +16 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q2 2014 was Baker Bros. Advisors, an estimated $48.9M added.
  • The largest BioCryst Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $16.7M sold.

Based on aggregated 13F filings for Q2 2014.